Grazyna Kochan

Universidad Publica de Navarra — Spain

Medicine · Health Sciences

38h-index6.2kcitations178works4.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(60), Immunotherapy and Immune Responses(31), CAR-T cell therapy research(30), Immune cells in cancer(29), Immune Cell Function and Interaction(21)

Publications178 total

148P High-throughput multiomic profiling of PD-1/LAG-3 signaling uncovers a highly dysfunctional T cell rewiring through MYC inhibition
ESMO Open·2025Open Access
Programmed Death-1 Ligand 1 Domain Organization, Signaling Motifs, and Interactors in Cancer Immunotherapy
Cancers·2025· 3 citedOpen Access
PD-L1 Domain Organization, Signaling Motifs and Interactors in Cancer Immunotherapy
Preprints.org·2025Open Access
110MO CD8 T cells are responsible for the PD-1, LAG-3 and CBL-B triple blockade therapeutic antitumor effect
ESMO Open·2024Open Access
4P CBL-B inhibition overcomes PD-1/LAG-3 mediated resistance in lung cancer
Annals of Oncology·2024Open Access
PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets
EMBO Molecular Medicine·2024· 14 citedOpen Access
Oleuropein-driven reprogramming of the myeloid cell compartment to sensitise tumours to PD-1/PD-L1 blockade strategies
British Journal of Cancer·2024· 12 citedOpen Access
Correction for Castaño-Rodriguez et al., “Role of Severe Acute Respiratory Syndrome Coronavirus Viroporins E, 3a, and 8a in Replication and Pathogenesis”
mBio·2023· 1 citedOpen Access
Assessment of myeloid-derived suppressor cell differentiation ex vivo
Methods in cell biology·2023
Circulating low density neutrophils are associated with resistance to anti‐PD1 immunotherapy in squamous head and neck cancer
Head & Neck·2023· 6 citedOpen Access
15P CBL E3 ubiquitin ligases are key inhibitory regulators in PD-1/LAG-3 co-signaling in human cancers, targeted through bispecific co-blockade
Annals of Oncology·2023Open Access
Metabolic rewiring induced by ranolazine improves melanoma responses to targeted therapy and immunotherapy
Nature Metabolism·2023· 44 citedOpen Access
Plasma fractalkine contributes to systemic myeloid diversity and <scp>PD‐L1</scp> / <scp>PD</scp> ‐1 blockade in lung cancer
EMBO Reports·2023· 11 citedOpen Access
Current Indications and Future Landscape of Bispecific Antibodies for the Treatment of Lung Cancer
International Journal of Molecular Sciences·2023· 6 citedOpen Access
mRNA Vaccines against SARS-CoV-2: Advantages and Caveats
International Journal of Molecular Sciences·2023· 73 citedOpen Access
PD-1/LAG-3 Dysfunctionality Signatures in Human Cancers
2023· 1 citedOpen Access
Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
Cancers·2023· 81 citedOpen Access
PD-L1, a Master Regulator of Immunity 2.0
International Journal of Molecular Sciences·2023Open Access
Leading Edge: Intratumor Delivery of Monoclonal Antibodies for the Treatment of Solid Tumors
International Journal of Molecular Sciences·2023· 16 citedOpen Access
Cutting-Edge CAR Engineering: Beyond T Cells
Biomedicines·2022· 9 citedOpen Access
page 1 of 9Next →

Frequent Co-authors

David Escors(31), Hugo Arasanz(20), Ana Bocanegra(16), Miren Zuazo(15), Udo Oppermann(14), Luisa Chocarro(13), María Gato(11), G. Fernández-Hinojal(9), Ester Blanco(9), Ruth Vera(8), Lucía Teijeira(7), Miriam Echaide(7), Ruth Vera(7), Leticia Fernández(6), Maider Garnica(6), Pablo Ramos(6), María Ibáñez-Vea(5), T. Krojer(5), Idoia Morilla(5), Christopher J. Schofield(5)